Jiong Lin
Not all major pathological responses are equal: prognostic heterogeneity and risk stratification after neoadjuvant chemoimmunotherapy in resectable NSCLC
BackgroundMajor pathological response (MPR) is a widely used efficacy endpoint for neoadjuvant chemoimmunotherapy (NCIT) in resectable non-small cell lung cancer (NSCLC). However, whether MPR without pathological complete response (pCR) represents a pr…